Oncology Precision Medicine Market
- 2026 年市場規模
- USD 190.50 Bn
- 2033 年預估規模
- USD 366.53 Bn
- 年複合成長率 CAGR
- 9.8%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Oncology Precision Medicine Market, By Component (Therapeutics, Diagnostics / Testing, Informatics & Decision Support, interoperability tools, Services), By Care Pathway Stage (Risk Assessment & Screening, Diagnosis & Tumor Classification, Therapy Selection, Treatment Monitoring, Recurrence Surveillance / MRD, and Clinical Trial Enrolment & Matching, By Technology (Genomics, Transcriptomics, Gene expression profiling / signatures, Proteomics / Protein biomarkers, Mass spectrometrybased proteomics, Cytogenetics & Structural Variation, Single-cell & spatial,Spatial transcriptomics / multiplex imaging), By Biomarker Type (Genetic biomarkers, Genomic signatures / global markers, Tumor mutational burden, Microsatellite instability, Homologous recombination deficiency, Expression / protein markers, Epigenetic biomarkers, MRD biomarkers), By Sample Type (Tissue-based, Blood-based, Whole blood, Other biofluids, Cytology samples), End User (Hospitals & cancer centers, Diagnostic laboratories, Academic & research institutes, Pharmaceutical & biotech companies, CROs / clinical trial networks, and Payers / HTA bodies), By Cancer Type (Solid Tumors, Hematologic Malignancies, and Rare Cancers / Tumor-agnostic Segments), By Reimbursement & Access Channel (Public Reimbursement, Private Reimbursement, Out-of-pocket / Self-pay, Hybrid coverage models, Patient Assistance / Access Programs, and Clinical trialfunded Testing), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
According to Coherent Market Insights, the global oncology precision medicine market is estimated to be valued at USD 190.50 Bn in 2026 and is expected to reach USD 366.53 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033. The global oncology precision medicine market represents a revolutionary paradigm shift in cancer treatment, fundamentally transforming how healthcare providers approach diagnosis, treatment selection, and patient care management. Precision medicine in oncology leverages advanced genomic sequencing, biomarker identification, molecular diagnostics, and artificial intelligence to deliver highly personalized therapeutic interventions tailored to individual patient profiles and specific tumor characteristics.
This innovative approach moves beyond the traditional one-size-fits-all treatment methodology, enabling clinicians to identify optimal therapeutic pathways based on genetic mutations, protein expressions, and cellular pathways unique to each patient's malignancy. The integration of cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsies, pharmacogenomics, and companion diagnostics has accelerated the development of targeted therapies, immunotherapies, and combination treatment protocols that demonstrate superior efficacy rates and reduced adverse effects. As healthcare systems worldwide increasingly adopt value-based care models and seek to improve patient outcomes while managing costs, precision medicine emerges as a critical solution that promises to enhance treatment response rates, minimize trial-and-error prescribing, and ultimately improve survival rates across various cancer types including lung, breast, colorectal, melanoma, and hematological malignancies.
Market Dynamics
The global oncology precision medicine market is propelled by several compelling drivers that continue to accelerate market expansion and adoption rates across healthcare institutions worldwide. The primary growth driver stems from the rapidly declining costs of genomic sequencing technologies, making precision diagnostics more accessible and economically viable for routine clinical implementation, while simultaneously increasing cancer incidence rates globally create an urgent demand for more effective, personalized treatment solutions.
Technological advancements in artificial intelligence, machine learning algorithms, and big data analytics enable healthcare providers to process vast amounts of genomic and clinical data, facilitating more accurate treatment predictions and drug selection processes. Government initiatives, regulatory support, and substantial investments in precision medicine research from both public and private sectors further accelerate market growth, with organizations like the U.S. FDA streamlining approval processes for companion diagnostics and targeted therapies.
However, the market faces significant restraints including high implementation costs for healthcare facilities, particularly in developing regions, complex regulatory frameworks that vary across different countries, and the need for specialized infrastructure and trained personnel to effectively utilize precision medicine technologies. Data privacy concerns, ethical considerations surrounding genetic testing, and limited reimbursement policies in certain healthcare systems also impede market penetration.
Nevertheless, substantial opportunities emerge from expanding applications in rare cancers, growing adoption of liquid biopsy technologies, increasing pharmaceutical partnerships for biomarker-driven drug development, and the potential for precision medicine integration into routine clinical workflows, particularly as healthcare digitization accelerates and personalized treatment becomes the standard of care across oncology practices globally.
Key Features of the Study
• This report provides in-depth analysis of the global oncology precision medicine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global oncology precision medicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann La Roche Ltd, Novartis AG, Pfizer Inc, AstraZeneca plc, Bristol Myers Squibb Company, Merck & Co Inc, Gilead Sciences Inc, Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN NV, BioNTech SE, Amgen Inc, Foundation Medicine Inc, Guardant Health, and Myriad Genetics Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global oncology precision medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology precision medicine market
Market Segmentation
• Component Insights (Revenue, USD Bn, 2021 - 2033)
o Therapeutics
Targeted therapies
Targeted biologics
Precision immuno-oncology
Cell & gene therapies
Radiotheranostics / targeted radionuclide therapies
Combination regimens
o Diagnostics / Testing
Companion diagnostics (CDx)
Complementary diagnostics
Comprehensive genomic profiling (CGP) panels
Minimal residual disease (MRD) testing
Pharmacogenomics (PGx) relevant to oncology regimens
o Informatics & Decision Support
Clinical decision support (CDS) / treatment matching engines
Variant interpretation & annotation platforms
Molecular tumor board (MTB) enablement software
Data integration (EHR/LIS/omics) & interoperability tools
o Services
Sample logistics, biobanking, and pre-analytics services
Bioinformatics services (pipeline, interpretation, reporting)
Clinical trial matching services
Real-world evidence (RWE) and outcomes analytics
Contract research / companion diagnostic development services
• Care Pathway Stage (Revenue, USD Bn, 2021 - 2033)
o Risk assessment & screening
o Diagnosis & tumor classification
o Therapy selection
o Treatment monitoring
Response monitoring
Resistance emergence detection
Dose/therapy optimization
o Recurrence surveillance / MRD
o Clinical trial enrolment & matching
• Technology (Revenue, USD Bn, 2021 - 2033)
o Genomics
Next-generation sequencing (NGS)
o Targeted panels
o Whole exome sequencing (WES)
o Whole genome sequencing (WGS)
o PCR / qPCR / ddPCR
o Sanger sequencing (confirmatory)
o Transcriptomics
RNA sequencing (RNA-seq)
Gene expression profiling / signatures
o Proteomics / Protein biomarkers
Immunohistochemistry (IHC)
Mass spectrometry–based proteomics (select settings)
o Cytogenetics & Structural Variation
FISH
Karyotyping (certain hematologic cancers)
o Epigenetics
DNA methylation profiling (select tumors)
o Liquid biopsy technologies
ctDNA / cfDNA
CTCs
Exosomes / extracellular vesicles (emerging)
o Single-cell & spatial
Single-cell sequencing (scRNA/scDNA)
Spatial transcriptomics / multiplex imaging
• Biomarker Type (Revenue, USD Bn, 2021 - 2033)
o Genetic biomarkers
Single nucleotide variants (SNVs)
Indels
Copy number variations (CNVs)
Gene fusions / rearrangements
Germline variants (hereditary cancer)
o Genomic signatures / global markers
Tumor mutational burden (TMB)
Microsatellite instability (MSI)
Homologous recombination deficiency (HRD)
o Expression / protein markers
Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
o Epigenetic biomarkers
Methylation signatures
o MRD biomarkers
Personalized tumor-informed MRD
Tumor-naïve MRD panels
• Sample Type (Revenue, USD Bn, 2021 - 2033)
o Tissue-based
FFPE tissue
Fresh frozen tissue
Core needle biopsy / surgical specimens
o Blood-based (liquid biopsy)
Plasma (ctDNA/cfDNA)
Whole blood (CTCs, RNA)
o Other biofluids
Urine, saliva, CSF (indication-dependent)
o Cytology samples
FNA, smears (select workflows)
• End User (Revenue, USD Bn, 2021 - 2033)
o Hospitals & cancer centers
o Diagnostic laboratories
Clinical pathology labs
Molecular/genetic labs
o Academic & research institutes
o Pharmaceutical & biotech companies
o CROs / clinical trial networks
o Payers / HTA bodies
• Cancer Type (Revenue, USD Bn, 2021 - 2033)
o Solid tumors
Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
o Hematologic malignancies
Leukemia, lymphoma, myeloma, MDS/MPN, etc.
o Rare cancers / tumor-agnostic segments
Tumor-agnostic biomarker-defined populations
• Reimbursement & Access Channel (Revenue, USD Bn, 2021 - 2033)
o Public reimbursement
o Private reimbursement
o Out-of-pocket / self-pay
o Hybrid coverage models
o Patient assistance / access programs
o Clinical trial–funded testing
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Hoffmann La Roche Ltd
o Novartis AG
o Pfizer Inc
o AstraZeneca plc
o Bristol Myers Squibb Company
o Merck & Co Inc
o Gilead Sciences Inc
o Illumina Inc
o Thermo Fisher Scientific Inc
o QIAGEN NV
o BioNTech SE
o Amgen Inc
o Foundation Medicine Inc
o Guardant Health
o Myriad Genetics Inc
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Oncology Precision Medicine Market, By Component
Global Oncology Precision Medicine Market, By Care Pathway Stage
Global Oncology Precision Medicine Market, By Technology
Global Oncology Precision Medicine Market, By Biomarker Type
Global Oncology Precision Medicine Market, By Sample Type
Global Oncology Precision Medicine Market, By End User
Global Oncology Precision Medicine Market, By Cancer Type
Global Oncology Precision Medicine Market, By Reimbursement & Access Channel
Global Oncology Precision Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trends
4. Global Oncology Precision Medicine Market, By Component, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Therapeutics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Targeted therapies
o Targeted biologics
o Precision immuno-oncology
o Cell & gene therapies
o Radiotheranostics / targeted radionuclide therapies
o Combination regimens
o Diagnostics / Testing
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Companion diagnostics (CDx)
o Complementary diagnostics
o Comprehensive genomic profiling (CGP) panels
o Minimal residual disease (MRD) testing
o Pharmacogenomics (PGx) relevant to oncology regimens
o Informatics & Decision Support
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Clinical decision support (CDS) / treatment matching engines
o Variant interpretation & annotation platforms
o Molecular tumor board (MTB) enablement software
o Data integration (EHR/LIS/omics) & interoperability tools
o Services
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Sample logistics, biobanking, and pre-analytics services
o Bioinformatics services (pipeline, interpretation, reporting)
o Clinical trial matching services
o Real-world evidence (RWE) and outcomes analytics
o Contract research / companion diagnostic development services
5. Global Oncology Precision Medicine Market, By Care Pathway Stage, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Risk Assessment & Screening
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Diagnosis & Tumor Classification
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Therapy Selection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Treatment Monitoring
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Response Monitoring
o Resistance Emergence Detection
o Dose/Therapy Optimization
o Recurrence Surveillance / MRD
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Clinical Trial Enrolment & Matching
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Precision Medicine Market, By Technology, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Genomics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Next-generation sequencing (NGS)
Targeted panels
Whole exome sequencing (WES)
Whole genome sequencing (WGS)
o PCR / qPCR / ddPCR
o Sanger sequencing (confirmatory)
o Transcriptomics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o RNA sequencing (RNA-seq)
o Gene expression profiling / signatures
o Proteomics / Protein biomarkers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Immunohistochemistry (IHC)
o Mass spectrometry–based proteomics (select settings)
o Cytogenetics & Structural Variation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o FISH
o Karyotyping (certain hematologic cancers)
o Epigenetics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o DNA methylation profiling (select tumors)
o Liquid biopsy technologies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o ctDNA / cfDNA
o CTCs
o Exosomes / extracellular vesicles (emerging)
o Single-cell & spatial
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Single-cell sequencing (scRNA/scDNA)
o Spatial transcriptomics / multiplex imaging
7. Global Oncology Precision Medicine Market, By Biomarker Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Genetic Biomarkers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Single nucleotide variants (SNVs)
o Indels
o Copy number variations (CNVs)
o Gene fusions / rearrangements
o Germline variants (hereditary cancer)
o Genomic Signatures / Global Markers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Tumor mutational burden (TMB)
o Microsatellite instability (MSI)
o Homologous recombination deficiency (HRD)
o Expression / Protein Markers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
o Epigenetic Biomarkers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Methylation signatures
o MRD Biomarkers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Personalized tumor-informed MRD
o Tumor-naïve MRD panels
8. Global Oncology Precision Medicine Market, By Sample Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Tissue-based
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o FFPE tissue
o Fresh frozen tissue
o Core needle biopsy / surgical specimens
o Blood-based (liquid biopsy)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Plasma (ctDNA/cfDNA)
o Whole blood (CTCs, RNA)
o Other Biofluids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Urine, saliva, CSF (indication-dependent)
o Cytology Samples
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o FNA, Smears (Select Workflows)
9. Global Oncology Precision Medicine Market, By End User, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospitals & cancer centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Diagnostic laboratories
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Clinical pathology labs
o Molecular/genetic labs
o Academic & research institutes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Pharmaceutical & biotech companies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o CROs / clinical trial networks
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Payers / HTA bodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Oncology Precision Medicine Market, By Cancer Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Solid Tumors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
o Hematologic Malignancies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Leukemia, lymphoma, myeloma, MDS/MPN, etc.
o Rare Cancers / Tumor-agnostic Segments
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Tumor-agnostic biomarker-defined populations
11. Global Oncology Precision Medicine Market, By Reimbursement & Access Channel, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Public Reimbursement
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Private Reimbursement
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Out-of-pocket / Self-pay
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Hybrid coverage models
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Patient Assistance / Access Programs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Clinical trial–funded Testing
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
12. Global Oncology Precision Medicine Market, By Region, 2021 - 2033, Value (USD Bn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
o South Africa
o North Africa
o Central Africa
13. Competitive Landscape
o Hoffmann La Roche Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Pfizer Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o AstraZeneca plc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Bristol Myers Squibb Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Merck & Co Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Gilead Sciences Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Illumina Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Thermo Fisher Scientific Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o QIAGEN NV
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o BioNTech SE
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Amgen Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Foundation Medicine Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Guardant Health
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Myriad Genetics Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
14. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
15. References and Research Methodology
o References
o Research Methodology
o About us
*Browse 32 market data tables and 28 figures on 'Oncology Precision Medicine Market' - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們